Acelot is a drug discovery company focusing on finding effective disease-modifying therapies with minimal side-effects for central nervous system diseases such as Alzheimer's and Parkinson's Disease.
Acelot's core advantage is a patented computer-aided drug target and lead discovery technology. It allows for the discovery of novel lead compounds directed to known targets and previously unknown drug targets within large biochemical pathways. The algorithms Acelot uses screen against undesired pathways and targets, thereby minimizing the risk of side-effects.
The current drug discovery pipeline includes the following mechanisms-of-action:
|Beta-amyloid oligomer antagonists (Alzheimer's Disease)||RXR agonists (Alzheimer's Disease)||LXR/PPAR modulators (Alzheimer's Disease)|